King Abdulaziz University

Virginia Commonwealth University

Tarek Abdelnapy Ahmed

Khalid Mohamed El-Say

Abdelsattar Mansour Omar

Raed Felimban

Osama A A Ahmed

Waleed Rizg

Omar D Al-hejaili

Hossam H Tayeb

Hossam Samir El-Sawy

Bader M Aljaeid

Martin K Safo

Nabil Abdulhafiz Alhakamy

Shaimaa M Badr-Eldin

Fuad Alnadwi

Fathy I Abd-Allah

Fuad H AlNadwi

Mohammed M Mussari

Maram M Alzahrani

Alaa O Bawazir

Hossam S El-Sawy

A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.

Buccal formulation of avanafil with enhanced bioavailability and prolonged duration

Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in a curcuma oil based self-nanoemulsifying drug delivery system (SNEDDS). The disclosure also provides a method of treating a metabolic disorder or disease by administering a therapeutically effective amount of the 3D-printed tablet to a subject in need thereof.

Methods for treating metabolic disorder

An ophthalmic formulation comprising transethosomes is provided. The transethosomes include a phospholipid, an edge activator, ethanol, and ketoconazole, wherein a surface of the transethosome is modified with a cationic charge inducing agent. The transethosomes may be incorporated into in situ gelling or hydrogel compositions. The formulations are useful for the sustained delivery of ketoconazole to the posterior eye segment of a subject.

Ketoconazole ophthalmic preparations containing trans-ethosomal drug nanoparticles

Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in aoil based self-nanoemulsifying drug delivery system (SNEDDS).

Self-nanoemulsifying 3D-printed tablet composition and method of use thereof

Chitosan-coated, flexible lipid-based nanoparticles are provided. The nanoparticles ('chitoplexes') comprise an interior comprising a mixture of a phospholipid, an edge activator, a charge inducing agent, and a statin; and an exterior chitosan coating which encapsulates the interior mixture. The chitoplexes exhibit enhanced bioavailability with respect to delivering the statins encapsulated therein to a subject, for example, for the treatment of cancer.

Drug loaded flexible chitoplexes nanoparticles

A transdermal film composition including a film forming polymer comprising poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) 1:2:0.2, oleic acid, polyethylene glycol, and atorvastatin calcium. Methods of making the composition and administering the composition to deliver atorvastatin to a subject are also provided.

Transdermal film formulations and methods of use

An in situ gel formulation comprising poly lactide-co-&#x3b5;-caprolactone (PLCL), a surfactant with a hydrophilic-lipophilic balance value of 14-15, a plasticizer, and a statin is provided. Methods of treating hyperlipidemia by parenterally administering the in situ gel formulation are also provided.

In situ gelling formulation for reduced initial drug burst

Micelle formulations comprising a tocopherol or derivative thereof, alpha lipoic acid, and a biologically active agent such as vinpocetine are provided. Films for transdermal delivery containing the micelle formulation and methods of treating cognitive and cerebrovascular disorders are also provided.

Micellles containing alpha lipoic acid as a transdermal drug delivery system

Methods of enhancing cognition and/or memory and methods of treating cognitive and cerebrovascular disorders by intranasally administering an in situ gelling composition comprising micelles formed with tocopherol or a derivative thereof are provided. The micelles encapsulate a biological active agent such as vinpocetine. The methods provide for enhanced brain targeting of the biological active agent.

In situ gelling composition containing tocopherol-loaded micelles as an intranasal drug delivery system

Mucoadhesive buccal films comprising a statin-hydroxypropyl-beta-cyclodextrin inclusion complex and a statin-loaded mixed micelle composition, wherein the ratio of the mixed micelle composition to the inclusion complex is from 2:0.5 to 2:1.5 are provided. Methods of improving permeation of a statin across mucosal tissue by administering the film to a subject are also provided.

Mucoadhesive buccal film having a dual release carrier system

Solid dosage pullulan-based buccal tablets containing a polyvinyl pyrrolidone and vinpocetine (e.g., lyophilized polyvinyl pyrrolidone vinyl acetate and vinpocetine), when administered via the buccal mucosa, provide increased bioavailability of the active agent. The formulations may be used to treat a variety of indications for which vinpocetine has been shown to have beneficial activity, and have particular utility in the treatment of cerebral degenerative diseases.

Growing community of inventors

Jeddah, Saudi Arabia

Tarek Abdelnapy Ahmed